Treatment of allergic reactions to peanut in recent versus initial reaction by Ben-Shoshan, Moshe et al.
POSTER PRESENTATION Open Access
Treatment of allergic reactions to peanut in
recent versus initial reaction
Moshe Ben-Shoshan
1*, Luu Nha Nguyen
2, Reza Alizadehfar
1, Lianne Soller
2, Joe Fragapane
2, Lawrence Joseph
2,3,
Yvan St Pierre
2, Laurie Harada
4, Carole Fortin
5, Mary Allen
6, Ann Clarke
2,7
From AllerGen NCE Inc.’s Fifth Annual Research Conference: Innovation from Cell to Society
Québec City, QC, Canada. 7-9 February 2010
Background
Although studies suggest underuse of epinephrine in
food related allergic reactions, it is not clear whether
treatment may differ over time in those who have
already had an allergic reaction. We sought to character-
ize treatment of the most recent allergic reaction to pea-
nut versus the initial allergic reaction.
Materials and methods
Individuals with an allergist-confirmed peanut allergy
were recruited from the Montreal Children’s Hospital
and Canadian food allergy advocacy organizations. Data
were collected on initial allergic reactions to peanut and
most recent reaction to peanut during the year prior to
study entry.
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Table 1
Epinephrine +/- other
medications
Other medications (excluding epinephrine) eg:
antihistamines
None
Initial reactions, % (95% CI) 8.9% (5.2, 14) 35.6% (28.6, 43) 55.6% (48, 62.9)
Mild 0.0% (0, 6.4) 28.6% (17.3, 42.2) 71.4% (57.8,
82.7)
Moderate 7.7% (3.1, 15.2) 37.4% (27.4, 48.1) 54.9% (44.2,
65.4)
Severe 27.3% (13.3, 45.5) 42.4% (25.5, 60.8) 30.3% (15.6,
48.7)
Treated only outside HCF 0.0% (0, 9.3) 100.0% (90.7, 100)
Treated only in HCF 44.8% (26.4, 64.3) 55.2% (35.7, 73.6)
Treated outside and in HCF 40% (5.3, 85.3) 60% (14.7, 94.7)
Location unknown 12.5% (0.3, 52.7) 87.5% (47.3, 99.7)
Most recent reactions % (95%
CI)
17.2% (12, 23.5) 62.2% (54.7, 69.3) 20.6% (14.9,
27.2)
Mild 5.7% (1.2, 15.7) 64.2% (49.8, 76.9) 30.2% (18.3,
44.3)
Moderate 16.5% (9.7, 25.4) 63.9% (53.5, 73.4) 19.6% (12.2,
28.9)
Severe 40% (22.7, 59.4) 53.3% (34.3, 71.7) 6.7% (0.8, 22.1)
Treated only outside HCF 8.8% (3.9, 16.6) 91.2% (83.4, 96.1)
Treated only in HCF 20% (2.5, 55.6) 80% (44.4, 97.5)
Treated outside and in HCF 64% (42.5, 82) 36% (18, 57.5)
Location unknown 29.4% (10.3, 56) 70.6% (44, 89.7)
CI, Confidence interval; HCF, Health Care facility
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See Table 1
Among 180 individuals reporting both an initial aller-
gic reaction and a recent allergic reaction to peanut, epi-
nephrine was administered in 8.9% (95% CI, 5.2-14.0%)
and 17.2% (95% CI, 12.0-23.5%) respectively. Treatments
excluding epinephrine were given in 35.6% (95% CI,
28.6-43.0%) of initial reactions and in 62.2% (95% CI,
54.7-69.3%) of most recent reactions. Among those trea-
ted only outside health care facilities (HCFs) no partici-
pant received epinephrine in initial reactions versus
almost 9% (95% CI, 3.9-16.6%) in most recent reactions.
However, in initial reactions, 44.8% (95% CI, 26.4-64.3%)
of those treated, only in HCFs received epinephrine
compared to 20% (95% CI, 2.5-55.6%) in recent reac-
tions. Almost 1/3(95% CI, 15.6-48.7%) of participants
with a severe reaction did not receive any treatment for
the initial reaction compared to 6.7% (95% CI, 0.8-
22.1%) of those with a recent reaction.
Conclusions
Although there is higher use of epinephrine in recent
reactions compared to initial reactions, it is still admi-
nistered in only 40% of severe allergic reactions. Further,
our results suggest decreased epinephrine use over time
in those treated initially in HCFs concurrent with
increased use of other treatments such as anti-hista-
mines. Given that prompt administration of epinephrine
is the principal therapy for food-related anaphylaxis, it is
crucial to develop and distribute guidelines and educa-
tion programs that would contribute to increase epi-
nephrine use inside and outside HCFs.
Author details
1Division of Pediatric Allergy and Clinical Immunology, Department of
Pediatrics, McGill University Health Center, Montreal, Canada.
2Division of
Clinical Epidemiology, Department of Medicine, McGill University Health
Center.
3Departments of Epidemiology and Biostatistics, McGill University,
Canada.
4Anaphylaxis Canada (AC), Canada.
5Association Québécoise des
Allergies Alimentaires (AQAA), Canada.
6Allergy/Asthma Information
Association (AAIA), Canada.
7Division of Allergy and Clinical Immunology,
Department of Medicine, McGill University Health Center, Canada.
Published: 26 November 2010
doi:10.1186/1710-1492-6-S3-P29
Cite this article as: Ben-Shoshan et al.: Treatment of allergic reactions to
peanut in recent versus initial reaction. Allergy, Asthma & Clinical
Immunology 2010 6(Suppl 3):P29.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ben-Shoshan et al. Allergy, Asthma & Clinical Immunology 2010, 6(Suppl 3):P29
http://www.aacijournal.com/content/6/S3/P29
Page 2 of 2